Literature DB >> 8017885

Influence of infection on exacerbations of multiple sclerosis.

H S Panitch1.   

Abstract

Exacerbations of multiple sclerosis (MS) are triggered by exogenous events, the best documented being viral upper respiratory infections (URIs), which can stimulate secretion of cytokines such as interferon-gamma (IFN-gamma) by immune cells. In conjunction with a recent clinical trial of systemic interferon-beta (IFN-beta) in relapsing-remitting MS, we studied the occurrence of viral infections and their correlation with MS attacks. Thirty patients kept daily logs, noting URI symptoms in themselves, family members, and co-workers. Patients were examined every 3 months, or whenever an attack of MS occurred, and were tested for antibodies to common upper respiratory pathogens. A strong correlation was found between MS attacks and URIs. There were 168 URIs in 2,792 patient-weeks, including 996 weeks at risk (the interval beginning 1 week before and ending 5 weeks after onset of URI symptoms) and 1,796 weeks not at risk. Nearly two-thirds of attacks occurred in periods at risk. Attack rates were 2.92 per year in weeks at risk compared to 1.16 per year in weeks not at risk, a significant difference (p < 0.001). High-dose interferon reduced the frequency of MS attacks, but had no effect on the number of URIs. Although a specific virus could not be incriminated, we concluded that URIs of presumed viral origin are an important trigger of MS attacks, and that treatment with IFN-beta reduces the attack rate, but not by preventing URIs. Rather, it may modulate responses to viral infection that would otherwise lead to immune activation and clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8017885      PMCID: PMC7159629          DOI: 10.1002/ana.410360709

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  5 in total

1.  Clinical viral infections and multiple sclerosis.

Authors:  W A Sibley; C R Bamford; K Clark
Journal:  Lancet       Date:  1985-06-08       Impact factor: 79.321

2.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

3.  Exacerbations of multiple sclerosis in patients treated with gamma interferon.

Authors:  H S Panitch; R L Hirsch; A S Haley; K P Johnson
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

4.  Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study.

Authors:  O Andersen; P E Lygner; T Bergström; M Andersson; A Vahlne
Journal:  J Neurol       Date:  1993-07       Impact factor: 4.849

5.  Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?

Authors:  J Beck; P Rondot; L Catinot; E Falcoff; H Kirchner; J Wietzerbin
Journal:  Acta Neurol Scand       Date:  1988-10       Impact factor: 3.209

  5 in total
  72 in total

Review 1.  Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors:  M P Keane; J P Lynch
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 2.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

3.  A new cell enzyme-linked immunosorbent assay demonstrates gamma interferon suppression by beta interferon in multiple sclerosis.

Authors:  M Bakhiet; V Ozenci; C Withagen; M Mustafa; S Fredrikson; H Link
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

4.  Correlation between interferon production and clinical disease activity in patients with multiple sclerosis.

Authors:  M Dettke; P Scheidt; H Prange; H Kirchner
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

5.  Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

Authors:  J Lycke; B Svennerholm; E Hjelmquist; L Frisén; G Badr; M Andersson; A Vahlne; O Andersen
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

6.  Multiple sclerosis. More genes versus environment.

Authors:  B H Waksman
Journal:  Nature       Date:  1995-09-14       Impact factor: 49.962

7.  A controlled study of potential risk factors preceding exacerbation in multiple sclerosis.

Authors:  C Gasperini; M G Grasso; M Fiorelli; E Millefiorini; S Morino; A Anzini; A Colleluori; M Salvetti; C Buttinelli; C Pozzilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-09       Impact factor: 10.154

8.  Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

Authors:  K Genç; D L Dona; A T Reder
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

9.  Cerebral expression of interleukin-12 induces neurological disease via differential pathways and recruits antigen-specific T cells in virus-infected mice.

Authors:  Markus Hofer; Jürgen Hausmann; Peter Staeheli; Axel Pagenstecher
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 10.  Transgenic models for cytokine-induced neurological disease.

Authors:  Iain L Campbell; Markus J Hofer; Axel Pagenstecher
Journal:  Biochim Biophys Acta       Date:  2009-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.